Business Wire

SWARM Biotactics Raised €13M to Advance Bio-Robotics From Lab to Field

24.6.2025 09:43:00 EEST | Business Wire | Press release

Share

SWARM Biotactics, developer of bio-robotic systems based on fully controllable living insects for mission-critical operations, has secured €10 million in seed funding, bringing its total raised to €13 million, including a €3 million pre-seed. The round was backed by a consortium of international investors from Europe, the United States, and Australia, including Vertex Ventures US, Possible Ventures, and Capnamic, who was the first investor in the pre-seed round. Several early backers also increased their stakes in the oversubscribed round.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623790761/en/

A SWARM Biotactics bio-robotic unit equipped with a custom sensor backpack for intelligence gathering in inaccessible terrain. (Photo: SWARM Biotactics)

UNMATCHED ACCESS FOR CRITICAL MISSIONS

SWARM Biotactics is creating a new category of robotics: living, intelligent systems designed for environments where machines can’t go—cluttered, denied, and high-risk terrain. Bio-robotic swarms consist of cockroaches equipped with a custom-built backpack for control, sensing, and secure communication—enabling precise navigation and real-time data collection in the most inaccessible places. SWARM delivers highly scalable bio-robotic systems for defense, security, and disaster response.

“We’re entering a decade where access, autonomy, and resilience define geopolitical advantage,” said Stefan Wilhelm, CEO of SWARM Biotactics. “Conventional systems fail where control is needed most—denied zones, collapsed infrastructure, politically complex terrain.

SWARM is the first company building an entirely new category of robotics: biologically integrated, AI-enabled, and mass-deployable systems for persistent intelligence in places no drone or ground robot can reach. This funding moves us from deep tech to deployment—delivering the infrastructure democracies need to operate more smartly, more safely, and with total tactical awareness.”

FROM DEEP TECH R&D TO OPERATIONAL READINESS

SWARM will use the new funding to transition from advanced research to field deployment. Priorities include:

  • Launching operational pilots in Europe and North America with defense, national security, and emergency response agencies.
  • Scaling production of proprietary sensor backpacks, neural interfaces, and swarm infrastructure.
  • Expanding its R&D centers and its international go-to-market and engineering hub.
  • Recruiting top talent in insect neurobiology, embedded AI, field robotics, and dual-use system integration.

“Our mission is to build a scalable, dual-use intelligence platform that adapts to any terrain, threat, or mission,” said Moritz Strube, CTO and co-founder. “This funding round validates the vision—and brings in the right global partners to help us scale.”

ABOUT SWARM BIOTACTICS

Founded in 2024, SWARM Biotactics develops fully controllable bio-robotic systems for defense, national security, disaster response, and industrial inspection. By combining biology with edge AI, swarm intelligence, and secure communications, SWARM delivers real-time data from the world’s most inaccessible places. The company is headquartered in Kassel, Germany, with a U.S. subsidiary in San Francisco, California.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250623790761/en/

Contacts

PRESS CONTACT
info@swarm-biotactics.com
www.swarm-biotactics.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.swarm-biota
ctics.com&esheet=54279567&newsitemid=20250623790761&lan=en-US&anchor=www.swarm-b
iotactics.com&index=1&md5=9b41749aa17fc3efdb2bd4d7b1c2fd59

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye